Clinical characteristics of the study groups
| Characteristics | ACEI/ARB (n=134) | Non-ACEI/ARB (n=116) | P value |
| Age (years) | 36.6±6.1 | 37.3±6.0 | 0.62 |
| Gender (male/female) | 77/57 | 63/53 | 0.74 |
| Admission systolic blood pressure (mm Hg) | 138±23 | 126±21 | 0.52 |
| Admission diastolic blood pressure (mm Hg) | 78±14 | 72±13 | 0.29 |
| Smoking | 10 (7.3) | 11 (9.2) | 0.45 |
| Laboratory data | |||
| White cell count (×109/L) | 7.8±2.6 | 7.4±2.3 | 0.54 |
| Hemoglobin (mg/dL) | 23,59± 3.06 | 21.91±3.06 | 0.60 |
| Hematocrit | 40.2±5 | 39.6±5 | 0.59 |
| Platelets, (×109/L) | 196±46 | 207±64 | 0.38 |
| Sedimentation | 45.8±27.8 | 47.3±26.7 | 0.88 |
| Glucose (mg/dL) | 90.8±9.2 | 88.7±9.2 | 0.32 |
| Blood urea nitrogen (mg/dL) | 14.1±5.2 | 14.2±5.6 | 0.24 |
| Creatinine (mg/dL) | 0.95±0.6 | 0.81±0.18 | 0.45 |
| Uric acid (mg/dL) | 6.1±1.9 | 4.9±1.3 | 0.48 |
| Lactate dehydrogenase (U/L) | 478±276 | 442±175 | 0.32 |
| AST (IU/L) | 25±10.6 | 24.5±9.5 | 0.82 |
| ALT (IU/L) | 33±19 | 34±19.5 | 0.84 |
| C reactive protein (mg/dL) | 38±79 | 40±84 | 0.92 |
| Fibrinogen (mg/L) | 549±138 | 521±152 | 0.45 |
| D-dimer (mg/L) | 1.14±2.1 | 1.24±2.3 | 0.81 |
| Creatine kinase (mg/dL) | 114±47 | 106±46 | 0.40 |
| CK-MB (mg/dL) | 0.88±0.51 | 0.72±0.43 | 0.82 |
| Troponin (µg/mL) | 13.1±40 | 14.3±43 | 0.93 |
| ProBNP (pg/mL) | 56±32 | 56.7±42 | 0.78 |
| Antihypertensive medications, n (%) | |||
| Calcium channel blockers | 45 (33.2) | 28 (24.3) | 0.17 |
| Beta blockers | 43 (31.5) | 32 (27.2) | 0.41 |
| Other medications, n (%) | |||
| Anticoagulant therapy | 7 (4.6) | 8 (6.9) | 0.31 |
| Aspirin | 45 (32.9) | 34 (29.5) | 0.09 |
| Furosemide | 9 (7.2) | 5 (4.4) | 0.30 |
| Statins | 32 (23.2) | 18 (15.8) | 0.28 |
| Left ventricular ejection fraction (%) | 58±12 | 55±10 | 0.25 |
| Metabolic equivalents | 7±3 | 8±4 | 0.18 |
ACEI, ACE inhibitor; ALT, alanine transaminase; ARB, angiotensin receptor blocker; AST, aspartate aminotransferase; BNP, brain natriuretic peptide; CK-MB, creatine kinase myocardial band.